U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H16N2O
Molecular Weight 180.2468
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RILMENIDINE

SMILES

C1CC1C(NC2=NCCO2)C3CC3

InChI

InChIKey=CQXADFVORZEARL-UHFFFAOYSA-N
InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)

HIDE SMILES / InChI

Molecular Formula C10H16N2O
Molecular Weight 180.2468
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Rilmenidine (brand names Albarel, Hyperium, Iterium and Tenaxum) is an imidazoline derivative used for the treatment of hypertension. Rilmenidine, an oxazoline compound with antihypertensive properties, acts on both medullary and peripheral vasomotor structures. Rilmenidine shows greater selectivity for imidazoline receptors than for cerebral alpha2-adrenergic receptors, distinguishing it from reference alpha2-agonists. Rilmenidine is as effective in monotherapy as all other first line classes of drugs, including diuretics, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and calcium antagonists. It is well tolerated and can be taken in combination for greater efficacy. Sedation and dry mouth are not prominent side effects and withdrawal hypertension is not seen when treatment is stopped abruptly. In addition to a reduction in blood pressure, Rilmenidine has been shown to improve glucose tolerance, lipid risk factors, and insulin sensitivity.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
43.9 nM [Ki]
177.8 nM [EC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tenaxum

Cmax

ValueDoseCo-administeredAnalytePopulation
3.49 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
3.28 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
7.85 ng/mL
2 mg single, oral
RILMENIDINE plasma
Homo sapiens
4.64 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
3.6 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
5.05 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
5.33 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
3.15 ng/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
38.33 ng × h/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
38.61 ng × h/mL
1 mg single, intravenous
RILMENIDINE plasma
Homo sapiens
78 ng × h/mL
1 mg single, oral
RILMENIDINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
8.31 h
1 mg single, intravenous
RILMENIDINE plasma
Homo sapiens
7.3 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
6.9 h
2 mg single, oral
RILMENIDINE plasma
Homo sapiens
13 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
18 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
23 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
34 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens
12 h
1 mg single, oral
RILMENIDINE plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
1 mg/day, up to 2 mg/day in divided doses
Route of Administration: Oral
In Vitro Use Guide
The cytotoxic activity of rilmenidine and doxorubicin on K562 cells was measured using the MTT assay. After treatment in 96-well plates, MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-dyphenyl tetrazolium bromide) (20 μL/well) was added to each well. Sampleswere incubated for a further 4 h, followed by the addition of 100 μl of 10% SDS. Absorbance at 570 nmwasmeasured the next day.
Substance Class Chemical
Record UNII
P67IM25ID8
Record Status Validated (UNII)
Record Version